Somatostatin Analogues Compared With Placebo and Other Pharmacologic Agents in the Management of Symptoms of Inoperable Malignant Bowel Obstruction: A Systematic Review

详细信息    查看全文

• 作者：George P. Obita ; MB ; ChB ; MPHCM ; MSc ; MFPH^a ; ^{gpobita@yahoo.co.uk} ; Elaine G. Boland ; MD ; MRCP ; PhD^b ; ^c ; David C. Currow ; BMed ; MPH ; PhD ; FRACP ; FAHMS^b ; ^d ; Miriam J. Johnson ; MBChB (Hons) ; FRCP ; MD^b ; Jason W. Boland ; MB ; BChir ; FRCP ; PhD^b
• 关键词：Inoperable malignant bowel obstruction ; palliative care ; somatostatin analogues ; octreotide ; randomized controlled trial ; vomiting
• 刊名：Journal of Pain and Symptom Management
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：52
• 期：6
• 页码：901-919.e1
• 全文大小：416 K
• 卷排序：52

文摘

Somatostatin analogues are commonly used to relieve symptoms in malignant bowel obstruction (MBO) but are more expensive than other antisecretory agents.ObjectivesTo evaluate the evidence of effectiveness of somatostatin analogues compared with placebo and/or other pharmacologic agents in relieving vomiting in patients with inoperable MBO.MethodsMEDLINE, EMBASE, CINAHL, and The Cochrane Controlled Trials Register databases were systematically searched; reference lists of relevant articles were hand searched. Cochrane risk of bias tool was used.ResultsThe search identified 420 unique studies. Seven randomized controlled trials (RCTs) met the inclusion criteria (six octreotide studies and one lanreotide); 220 people administered somatostatin analogues and 207 placebo or hyoscine butylbromide. Three RCTs compared a somatostatin analogue with placebo and four with hyoscine butylbromide. Two adequately powered multicenter RCTs with a low Cochrane risk of bias reported no significant difference between somatostatin analogues and placebo in their primary end points. Four RCTs with a high/unclear Cochrane risk of bias reported that somatostatin analogues were more effective than hyoscine butylbromide in reducing vomiting.ConclusionThere is low-level evidence of benefit with somatostatin analogues in the symptomatic treatment of MBO. However, high-level evidence from trials with low risk of bias found no benefit of somatostatin analogues for their primary outcome. There is debate regarding the clinically relevant study end point for symptom control in MBO and when it should be measured. The role of somatostatin analogues in this clinical situation requires further adequately powered, well-designed trials with agreed clinically important end points and measures.